Oncorus, Inc. (NASDAQ:ONCR) Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its holdings in shares of Oncorus, Inc. (NASDAQ:ONCR) by 140.5% in the second quarter, HoldingsChannel reports. The firm owned 17,560 shares of the company’s stock after buying an additional 10,260 shares during the period. New York State Common Retirement Fund’s holdings in Oncorus were worth $242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Letko Brosseau & Associates Inc. lifted its position in Oncorus by 25.3% during the second quarter. Letko Brosseau & Associates Inc. now owns 24,750 shares of the company’s stock valued at $342,000 after purchasing an additional 5,000 shares during the period. We Are One Seven LLC acquired a new position in shares of Oncorus in the second quarter worth about $1,606,000. Luminus Management LLC acquired a new position in shares of Oncorus in the first quarter worth about $6,101,000. Morgan Stanley raised its position in shares of Oncorus by 2,605.4% in the first quarter. Morgan Stanley now owns 192,898 shares of the company’s stock worth $2,685,000 after acquiring an additional 185,768 shares during the period. Finally, Tudor Investment Corp Et Al acquired a new position in shares of Oncorus in the first quarter worth about $784,000. Institutional investors own 79.50% of the company’s stock.

Shares of Oncorus stock opened at $9.39 on Tuesday. The firm has a 50-day simple moving average of $11.44 and a two-hundred day simple moving average of $13.81. The company has a market cap of $241.78 million and a P/E ratio of -0.40. Oncorus, Inc. has a fifty-two week low of $9.10 and a fifty-two week high of $37.86.

Oncorus (NASDAQ:ONCR) last issued its quarterly earnings data on Wednesday, August 4th. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.04). As a group, sell-side analysts expect that Oncorus, Inc. will post -2.5 earnings per share for the current fiscal year.

About Oncorus

Oncorus, Inc, a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Featured Story: Liquidity

Want to see what other hedge funds are holding ONCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oncorus, Inc. (NASDAQ:ONCR).

Institutional Ownership by Quarter for Oncorus (NASDAQ:ONCR)

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.